Samsung Electronics
Search results
Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars. SAMSUNG BIOEPIS Contact Us
Apr 20, 2022 · • Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary. • First payment completed funded through paid in capital. • Accelerated growth expected in biosimilars and future novel therapeutics R&D.
4 days ago · PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States ...
3 days ago · Samsung Bioepis has announced US Food and Drug Administration (FDA) approval for PYZCHIVA (ustekinumab-ttwe / SB17) as a biosimilar to Stelara (ustekinumab). The approval includes subcutaneous injections of 45 mg/0.5 mL and 90 mg/mL, and an intravenous 130 mg/26 mL solution of the product. PYZCHIVA is indicated for multiple conditions including ...
Samsung Bioepis has successfully launched five biosimilars globally, three in autoimmune and two in oncology. Additionally, one product is about to be released in the market, and four biosimilars are in Phase 3 clinical trials.
Samsung Bioepis is a biopharmaceutical company dedicated to accelerating access to biologic medicines by bringing high-quality, clinically proven biosimilars to patients who need them. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek.
3 days ago · Samsung Bioepis has seven biosimilars approved in the US and four commercially available as of June 2024. Pyzchiva (ustekinumab-ttwe) is indicated for: Plaque psoriasis: Pyzchiva is indicated for the treatment of adults and paediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
